Tobacco Dependence Treatment Toolkit

References

  1. Fiore MC, Jaén CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update – Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service, 2008
  2. California Thoracic Society. Medical Management for Tobacco Dependence. Position Paper. Tustin (California, USA): California Thoracic Society, 2005
  3. Hill HA, Schoenbach VJ, Kleinbaum DG, et al. A longitudinal analysis of predictors of quitting smoking among participants in a self-help intervention trial. Addict Behav 1994; 19:159-173
  4. Cigarette smoking among adults – United States, 1995. Morbidity and Mortality Weekly Report, MMWR 1997, 1997; 1217-1220
  5. Pierce JP, Gilpin EA. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. JAMA 2002; 288:1260-1264
  6. Russell MA, Wilson C, Taylor C, et al. Effect of general practitioners’ advice against smoking. Br Med J 1979; 2:231-235
  7. National Asthma Education and Prevention Program: Expert Panel Report 3 (EPR-3):Guidelines for the Diagnosis and Management of Asthma -Summary Report 2007. J Allergy Clin Immunol. 2007 Nov;120(5 Suppl):S94-138.
  8. Coding for chest medicine 2009. Northbrook: American College of Chest Physicians, 2008
  9. Coy J. CPT Handbook for Office-Based Coding: American Medical Association Press, 2008
  10. Medicare Learning Network (Medlearn). Smoking and Tobacco Use Cessation Counseling: Centers for Medicare and Medicaid Services, 2005
  11. Commission on Professional and Hospital Activities. The International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM), Volume 2: Diseases: Alphabetic Index. Ann Arbor (MI), 1979
  12. ACCP. 2009 Pulmonary PQRI Performance Measures, 2009
  13. United States Department of Veterans Affairs. Elimination of Copayment for Smoking Cessation Counseling. Federal Register 2006; 71:2464
  14. United States Department of Veterans Affairs: Public Health Strategic Health Care Group. Smoking Cessation: Elimination of Co-payment FAQ, 2007
  15. Sherman SE. A framework for tobacco control: lessons learnt from Veterans Health Administration. BMJ 2008; 336:1016-1019
  16. CDC. State Medicaid Coverage for Tobacco-Dependence Treatments – United States, 2005. MMWR 2006; 55:1194-1197
  17. CDC. State Medicaid Coverage for Tobacco-Dependence Treatments – United States, 2006. MMWR 2008; 57:117-122
  18. Fiore MC, Pierce JP, Remington PL, et al. Cigarette smoking: the clinician’s role in cessation, prevention, and public health. Dis Mon 1990; 36:181-242
  19. Bierer M, Rigotti N. Public Policy for the control of tobacco-related disease. Medical Clinics of North America 1992; 76:515-539
  20. Cromwell J, Bartosch WJ, Fiore MC, et al. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research. JAMA 1997; 278:1759-1766
  21. Croghan IT, Offord KP, Evans RW, et al. Cost-effectiveness of treating nicotine dependence: the Mayo Clinic experience. Mayo Clin Proc 1997; 72:917-924
  22. Lightwood JM, Glantz SA. Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke. Circulation 1997; 96:1089-1096
  23. CDC. State Medicaid Coverage for Tobacco-Dependence Treatments – United States, 1994-2002. MMWR 2004; 53:54-57
  24. United States Department of Veterans Affairs: Public Public and Intergovernmental Affairs. Fact Sheet: Facts About the Department of Veterans Affairs, 2008
  25. United States Department of Veterans Affairs: Veterans Health Administration Office of the Assistant Deputy Under Secretary for Health (ADUSH) for Policy and Planning. 2007 Survey of Veteran Enrollee’s Health and Reliance Upon VA with Selected Comparisons to the 1999 – 2005 Surveys, 2008
  26. CDC. Cigarette smoking among adults–United States, 2006. MMWR Morb Mortal Wkly Rep 2007; 56:1157-1161
  27. Jonk YC, Sherman SE, Fu SS, et al. National trends in the provision of smoking cessation aids within the Veterans Health Administration. Am J Manag Care 2005; 11:77-85
  28. CDC. Cigarette Smoking among Adults – United States, 1999. MMWR 2001; 50:869-873
  29. United States Department of Veterans Affairs: Veterans Health Administration. VHA Directive 2008-081: National Smoking and Tobacco Use Cessation Program, 2008
  30. United States Department of Veterans Affairs: Department of Defense, Office of Quality and Performance, Management of Tobacco Use Working Group. VA/DoD Clinical Practice Guideline for the Management of Tobacco Use, Update Version 2.0a, June 2003/June 2004
  31. Hamlett-Berry KW. Director, Office of Public Health Policy and Prevention, Public Health Strategic Health Care Group (13B), Department of Veterans Affairs. Personal Communication, 2008
  32. United States Department of Veterans Affairs: Department of Defense, Office of Quality and Performance, Management of Tobacco Use Working Group. Introduction to the VA/DoD Clinical Practice Guideline for the Management of Tobacco Use, Update Version 2.0a, June 2003/June 2004
  33. United States Department of Veterans Affairs: Public Health Strategic Health Care Group. Smoking Cessation: Best Practices in Tobacco Control within the VA: Programs to Support Treatment In Primary or Mental Health Care, 2007
  34. United States Department of Veterans Affairs: Department of Defense, Office of Quality and Performance. VA/DoD Clinical Practice Guideline for the Management of Tobacco Use: About Us – Areas of Service: Performance Measurement Program, 2001
  35. Hamlett-Berry KW. Smoking Cessation Policy in the VA Health Care System: Where Have We Been and Where Are We Going? in VA in the Vanguard: Building on Success in Smoking Cessation, Conference Proceedings, September 21, 2004, p.7-29., 2004
  36. United States Department of Veterans Affairs: Public Health Strategic Health Care Group. Smoking Cessation: Clinical Topics in Tobacco Cessation: VA Formulary Choices for Pharmacotherapy of Smoking Cessation: Smoking cessation table 2008, 2008; downloadable table of VA Formulary Choices (MS Word document)
  37. United States Department of Veterans Affairs: VA Health Care Eligibility & Enrollment. Outpatient Prescription Copay, 2008
  38. United States Department of Veterans Affairs: VA Health Care Eligibility & Enrollment. 2008 Copay Rates (Fact Sheet 16-1), 2008
  39. United States Department of Veterans Affairs: VA Health Care Eligibility & Enrollment. 2008 Copay Requirements at a Glance (Fact Sheet 164-8), 2008
  40. CDC. Cigarette smoking among adults–United States, 2007. MMWR Morb Mortal Wkly Rep 2008; 57:1221-1226
  41. Goldstein A. Project Manager: Regional Health Education, The Permanente Medical Group, Inc. Personal Communication, 2008
  42. Kaiser Permanente. Pharmacy Benefits PBN #2007-04 v2. This internal benefits document states the Kaiser Permanente policy regarding tobacco-dependence medications benefits for Kaiser Permanente members., 2007
  43. The Permanente Medical Group: Regional Health Education. Tobacco Cessation: Clinical Recommendations. This evidence-based guideline was developed to assist physicians and other health care professionals in providing counseling and treatment for cessation of tobacco use. Adapted from Southern California Medical Group CPG. Kaiser Permanente internal document: Clinical Recommendations for Tobacco Cessation 2008.pdf, 2008
  44. Pacific Business Group on Health (PBGH). Tobacco Cessation Benefit Coverage and Consumer Engagement Strategies: A California Perspective, June 2008
  45. Fiore MC, Bailey WC, Cohen SJ, et al. Smoking Cessation. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 1996
  46. Shiffman S, Scharf D, Shadel W, et al. Analyzing milestones in smoking cessation: illustration in a nicotine patch trial in adult smokers. Journal of Consulting & Clinical Psychology 2006; 74:276-285
  47. Shiffman S. Reflections on smoking relapse research. Drug & Alcohol Review 2006; 25:15-20
  48. Hughes JR, Keely JP, Niaura RS, et al. Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob Res 2003; 5:13-25
  49. Hughes JR, Gulliver SB, Fenwick JW, et al. Smoking cessation among self-quitters. Health Psychol 1992; 11:331-334
  50. Ferguson SG, Shiffman S, Gwaltney CJ. Does reducing withdrawal severity mediate nicotine patch efficacy? A randomized clinical trial. J Consult Clin Psychol 2006; 74:1153-1161
  51. Sachs DPL. Nicotine withdrawal medications. Tobacco Control 1993; 2:S42-S47
  52. Glover ED, Sachs DPL, Stitzer ML, et al. Smoking cessation in highly dependent smokers with 4-mg nicotine polacrilex. American Journal of Health Behavior 1996; 20:319-332
  53. Shiffman S, Ferguson SG, Gwaltney CJ, et al. Reduction of abstinence-induced withdrawal and craving using high-dose nicotine replacement therapy. Psychopharmacology (Berl) 2006; 184:637-644
  54. Hurt RD, Sachs DPL, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337:1195-1202
  55. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296:56-63
  56. Shiffman S, Ferguson SG, Gwaltney CJ. Immediate hedonic response to smoking lapses: relationship to smoking relapse, and effects of nicotine replacement therapy. Psychopharmacology (Berl) 2006; 184:608-618
  57. Dale LC, Hurt RD, Offord KP, et al. High-dose nicotine patch therapy. Percentage of replacement and smoking cessation. JAMA 1995; 274:1353-1358
  58. Sachs DPL, Benowitz NL, Bostrom AG, et al. Percent serum replacement and success of nicotine patch therapy. Am J Respir Crit Care Med 1995; 151:A688
  59. Transdermal Nicotine Study Group. Transdermal nicotine for smoking cessation: Six-month results from two multicenter controlled clinical trials. JAMA 1991; 266:3133-3138
  60. Hughes JR, Lesmes GR, Hatsukami DK, et al. Are higher doses of nicotine replacement more effective for smoking cessation? Nicotine Tob Res 1999; 1:169-174.
  61. Tønnesen P, Paoletti P, Gustavsson G, et al. Higher dosage nicotine patches increase one-year smoking cessation rates: Results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. European Respiratory Society. Eur Respir J 1999; 13:238-246
  62. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340:685-691
  63. Evins A, Cather C, Culhane M, et al. A 12-week double-blind, placebo-controlled study of bupropion SR added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. Journal of Clinical Psychopharmacology 2007; 27:380-386
  64. Jamerson BD, Nides M, Jorenby DE, et al. Late-term smoking cessation despite initial failure: an evaluation of bupropion sustained release, nicotine patch, combination therapy, and placebo. Clin Ther 2001; 23:744-752
  65. Shiffman S, Shadel W, Niaura R, et al. Efficacy of acute administration of nicotine gum in relief of cue-provoked cigarette craving. Psychopharmacology. Psychopharmacology 2003; 166:343-350
  66. Kornitzer M, Bousten M, Thijs J, et al. Efficiency and safety of combined use of nicotine patches and nicotine gum in smoking cessation: A placebo controlled double-blind trial. Eur Resp J 1993; 6:630
  67. Fagerstrom K. Combined use of nicotine replacement products. Health Values 1994; 18:15-20
  68. Puska P, Korhonen HJ, Vartiainen E, et al. Combined use of nicotine patch and gum compared with gum alone in smoking cessation: A clinical trial in North Karelia. Tobacco Control 1995; 4:231-235
  69. Blöndal T, Gudmundsson LJ, Olafsdottir I, et al. Nicotine nasal spray with nicotine patch for smoking cessation: Randomised trial with six-year follow up. Bmj 1999; 318:285-288
  70. Stapleton J. Commentary: Progress on nicotine replacement therapy for smokers. BMJ 1999; 318:289
  71. Benowitz NL, ed. Nicotine Safety and Toxicity. New York: Oxford University Press, 1998
  72. Henningfield JE. Nicotine medications for smoking cessation. N Engl J Med 1995; 333:1196-1203
  73. Tonstad S, Tønnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006; 296:64-71
  74. Williams KE, Reeves KR, Billing CB, Jr., et al. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin 2007; 23:793-801
  75. Fiore MC, Smith SS, Jorenby DE, et al. The effectiveness of the nicotine patch for smoking cessation. A meta-analysis. JAMA 1994; 271:1940-1947
  76. Nides M, Rakos R, Gonzales D, et al. Predictors of initial smoking cessation and relapse through the first 2 years of the Lung Health Study. J Consult Clin Psychol 1995; 63:60-69
  77. Marks MJ, Burch JB, Collins AC. Effects of chronic nicotine infusion on tolerance development and nicotine receptors. J Pharmacol Exp Ther 1983; 226:816-825
  78. Schwartz RD, Kellar KJ. Nicotinic cholinergic receptor binding sites in the brain: regulation in vivo. Science 1983; 220:214-216
  79. Marks MJ, Stitzel JA, Collins AC. Time-course study of the effects of chronic nicotine infusion on drug response and brain receptors. J Pharmacol Exp Ther 1985; 235:619-628
  80. Schwartz RD, Kellar KJ. In vivo regulation of [3H]acetylcholine recognition sites in brain by nicotinic cholinergic drugs. J Neurochem 1985; 45:427-433
  81. Benwell ME, Balfour DJK, Anderson JM. Evidence that tobacco smoking increases the density of H3-nicotine binding sites in human brain. J Neurochem 1988; 50:1243-1247
  82. Terry DC, Davila-Garcia MI, Stockmeier CA, et al. Binding to nicotinic receptors labeled by H3-epibatidine and H3-cytisine is increased in brains of smokers. Society for Neuroscience, 1996; 1273
  83. Breese CR, Marks MJ, Logel J, et al. Effect of smoking history on H3-nicotine binding in human, post-mortem brain. J Pharmacol Exp Ther 1997; 282:7-13
  84. Hughes JR. Tobacco withdrawal in self-quitters. J Consult Clin Psychol 1992; 60:689-697
  85. Henningfield JE. Behavioral pharmacology of cigarette smoking. Adv Behav Pharmacol 1984; 4:131-210
  86. Henningfield JE, Stapleton JM, Benowitz NL, et al. Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alcohol Depend 1993; 33:23-29.
  87. Grenhoff J, Aston-Jones G, Svensson TH. Nicotinic effects on the firing pattern of midbrain dopamine neurons. Acta Physiol Scand 1986; 128:351-358
  88. Grenhoff J, Svensson TH. Selective stimulation of limbic dopamine activity by nicotine. Acta Physiol Scand 1988; 133:595-596
  89. Svensson TH, Tung C-S. Local cooling of the prefrontal cortex induces pacemaker-like firing of dopamine neurons in rat ventral tegmental area in vivo. Acta Physiol Scand 1989; 136:135-136
  90. Tung C-S, Grenhoff J, Svensson TH. Nicotine counteracts midbrain dopamine cell dysfunction induced by prefrontal cortex inactivation. Acta Physiol Scand 1990; 138:427-428
  91. Nisell M, Nomikos GG, Svensson TH. Infusion of nicotine in the ventral tegmental area or the nucleus accumbens of the rat differentially affects accumbal dopamine release. Pharmacol Toxicol 1994; 75:348-352
  92. Nisell M, Nomikos GG, Svensson TH. Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area. Synapse 1994; 16:36-44
  93. Nisell M, Nomikos GG, Svensson TH. Nicotine dependence, midbrain dopamine systems and psychiatric disorders. Pharmacol Toxicol 1995; 76:157-162
  94. Marshall DL, Redfern PH, Wonnacott S. Presynaptic nicotinic modulation of dopamine release in the three ascending pathways studied by in vivo microdialysis: Comparison of naive and chronic nicotine-treated rats. J Neurochem 1997; 68:1511-1519
  95. Herning RI, Jones RT, Bachman J. EEG changes during tobacco withdrawal. Psychophysiology 1983; 20:507-512
  96. Henningfield JE, Keenan RM, Clarke PBS. Nicotine. In: Schuster CR, Kuhar MJ, eds. Pharmacological Aspects of Drug Dependence: Toward an Integrated Neurobehavioral Approach. Berlin: Springer-Verlag, 1996; 271-314
  97. American Psychiatric Association. Nicotine-induced disorder. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington, DC: American Psychiatric Association, 1994; 244-245
  98. Hughes JR, Hatsukami DK, Pickens RW, et al. Effect of nicotine on the tobacco withdrawal syndrome. Psychopharmacology 1984; 83:82-87
  99. Nemeth-Coslett R, Henningfield JE, O’Keeffe MK, et al. Nicotine gum: dose-related effects on cigarette smoking and subjective ratings. Psychopharmacology (Berl) 1987; 92:424-430
  100. Sachs DPL, Benowitz NL. Are smokers trying to stop and smokers not trying to stop the same experimental model? NIDA Res Monogr 1989; 95:366-367
  101. Hall SM, Reus VI, Munoz RF, et al. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch Gen Psychiatry 1998; 55:683-690
  102. Russell MA, Merriman R, Stapleton J, et al. Effect of nicotine chewing gum as an adjunct to general practitioner’s advice against smoking. Br Med J (Clin Res Ed) 1983; 287:1782-1785
  103. Garvey AJ, Bliss RE, Hitchcock JL, et al. Predictors of smoking relapse among self-quitters: A report from the Normative Aging Study. Addictive Behaviors 1992; 17:367-377
  104. Nørregaard J, Tønnesen P, Petersen L. Predictors and reasons for relapse in smoking cessation with nicotine and placebo patches. Prev Med 1993; 22:261-271
  105. Killen JD, Fortmann SP. Craving is associated with smoking relapse: findings from three prospective studies. Exp Clin Psychopharmacol 1997; 5:137-142
  106. West RJ, Hajek P, Belcher M. Severity of withdrawal symptoms as a predictor of outcome of an attempt to quit smoking. Psychol Med 1989; 19:981-985
  107. Bars MP, Banauch GI, Appel D, et al. “Tobacco Free With FDNY”: the New York City Fire Department World Trade Center Tobacco Cessation Study. Chest 2006; 129:979-987
  108. Sachs DPL. Tobacco dependence treatment: time to change the paradigm. Chest 2006; 129:836-839
  109. Steinberg MB, Foulds J, Richardson DL, et al. Pharmacotherapy and smoking cessation at a tobacco dependence clinic. Prev Med 2006; 42:114-119
  110. Allen S, Bade T, Hatsukami D, et al. Craving, withdrawal, and smoking urges on days immediately prior to smoking relapse. Nicotine Tob Res 2008; 10:35-45
  111. Prochaska JO. Assessing how people change. Cancer 1991; 67:805-807
  112. Sachs DPL. Tobacco dependence: Pathophysiology and treatment. In: Hodgkin JE, Celli BR, Connors GL, eds. Pulmonary Rehabilitation: Guidelines to Success, 3rd Edition. Philadelphia: Lippincott Williams & Wilkins, Inc., 2000; 261-301
  113. Sachs DPL. Medical Managememt of Tobacco Dependence: Concepts & Treatment Objectives. In: Hodgkin JE, Celli BR, Connors GL, eds. Pulmonary Rehabilitation: Guidelines to Success, 4th Edition. St. Louis, MO: Elsevier, 2008; (In Press)
  114. Cummings S, Rubin S, Oster G. The cost-effectiveness of counseling smokers to quit. JAMA 1989; 261:75-79
  115. Eddy D. David Eddy ranks the tests. Harvard Health Letter 1992; 11
  116. Sachs D. The biology of nicotine addiction: an educational aid for primary care physicians. Palo Alto: Palo Alto Center for Pulmonary Disease Prevention, 1997
  117. Shiffman S, Read L, Jarvik ME. Smoking relapse situations: a preliminary typology. Int J Addict 1985; 20:311-318
  118. Shiffman SM, Read L, Maltese J, et al. Preventing relapse in ex-smokers: A self management approach. In: Marlatt GA, Gordon JR, eds. Relapse Prevention: Maintenance Strategies in the Treatment of Addictive Behaviors. New York: Guilford Press, 1985; 472-520
  119. Shiffman S. A cluster-analytic classification of smoking relapse episodes. Addict Behav 1986; 11:295-307
  120. Bliss RE, Garvey AJ, Heinold JW, et al. The influence of situation and coping on relapse crisis outcomes after smoking cessation. Journal of Consulting and Clinical Psychology 1989; 57:443-449
  121. Shiffman S, Paty JA, Gnys M, et al. First lapses to smoking: within-subjects analysis of real-time reports. J Consult Clin Psychol 1996; 64:366-379
  122. O’Connell KA, Hosein VL, Schwartz JE. Thinking and/or Doing as Strategies for Resisting Smoking. Research in Nursing & Health 2006; 29:533-542
  123. Shiffman SM. Coping with temptations to smoke. J Consult Clin Psychol 1984; 52:261-267
  124. Shiffman S, Hickcox M, Paty JA, et al. Progression from a smoking lapse to relapse: prediction from abstinence violation effects, nicotine dependence, and lapse characteristics. J Consult Clin Psychol 1996; 64:993-1002
  125. Sachs DPL, Hodgkin JE, Bostrom AG. Improving Treatment Outcome In the Face of Increasingly Severe Nicotine Dependence in Patients Seeking Tobacco-Dependence Treatment. Chest 2008; 134(suuppl):eXX
  126. Benowitz NL, Jacob P 3rd. Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin Pharmacol Ther 1994; 56:483-493.
  127. Fagerström KO. Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav 1978; 3:235-241
  128. Heatherton TF, Kozlowski LT, Frecker RC, et al. The Fagerström Test for Nicotine Dependence: A Revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991; 86:1119-1127
  129. Nicotine Anonymous World Services. Introducing Nicotine Anonymous. Huntington Beach (CA): Nicotine Anonymous World Services, 2000; 8
  130. Nicotine Anonymous World Services. The Twelve Steps of Nicotine Anonmymous. Nicotine Anonymous Publications, Literature and Pamphlets, 2008; 3
  131. Morris JF, Temple W. Spirometric “lung age” estimation for motivating smoking cessation. Preventive Medicine 1985; 14:665-662
  132. Risser NL, Belcher DW. Adding spirometry, carbon monoxide, and pulmonary symptom results to smoking cessation counseling: A randomized trial. J Gen Intern Med 1990; 5:16-22
  133. Parkes G, Greenhalgh T, Griffin M, et al. Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. BMJ 2008; 336:598-600
  134. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: The Lung Health Study. JAMA 1994; 272:1497-1505
  135. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002; 166:675-679
  136. Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005; 142:233-239
  137. Hays JT, Hurt RD, Rigotti NA, et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial. Ann Intern Med 2001; 135:423-433
  138. Hall SM, Humfleet GL, Reus VI, et al. Extended nortriptyline and psychological treatment for cigarette smoking. Am J Psychiatry 2004; 161:2100-2107
  139. Kozlowski LT, Giovino GA, Edwards B, et al. Advice on using over-the-counter nicotine replacement therapy-patch, gum, or lozenge-to quit smoking. Addict Behav 2007; 32:2140-2150
  140. Sweeney CT, Fant RV, Fagerstrom KO, et al. Combination nicotine replacement therapy for smoking cessation: rationale, efficacy and tolerability. CNS Drugs 2001; 15:453-467
  141. Bohadana AB, Nilsson F, Rasmussen T, et al. Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: A randomized, double-blind, placebo-controlled trial. Arch Intern Med 2000; 160:3128-3134
  142. Croghan GA, Sloan JA, Croghan IT, et al. Comparison of nicotine patch alone versus nicotine nasal spray alone versus a combination for treating smokers: a minimal intervention, randomized multicenter trial in a nonspecialized setting. Nicotine Tob Res 2003; 5:181-187
  143. Rose JE, Behm FM, Westman EC, et al. Precessation treatment with nicotine skin patch facilitates smoking cessation. Nicotine Tob Res 2006; 8:89-101
  144. Hall W. The prospects for tobacco harm reduction. Intnl J Drug Policy 2005; 16:139-142
  145. Nordstrom B, Kinnunen T, Quiles Z, et al. Association between reduced smoking and long-term mortality risk, 2002
  146. Eliasson B, Hjalmarson A, Kruse E, et al. Effect of smoking reduction and cessation on cardiovascular risk factors. Nicotine Tob Res 2001; 3:249-255
  147. Stratton K, Shetty P, Wallace R, et al. Clearing the smoke: assessing the science base for tobacco harm reduction. . Washington: Institute of Medicine, 2001; 231-240
  148. Ferguson JA, Patten CA, Schroeder DR, et al. Predictors of 6-month tobacco abstinence among 1224 cigarette smokers treated for nicotine dependence. Addict Behav 2003; 28:1203-1218
  149. Sachs DPL, Säwe U, Leischow SJ. Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group counseling. Arch Intern Med 1993; 153:1881-1890
  150. Dale LC, Glover ED, Sachs DPL, et al. Bupropion for smoking cessation: Predictors of successful outcome. Chest 2001; 119:1357-1364
  151. Franken F, Pickworth W, Epstein D, et al. Smoking rates and topography predict adolescent smoking cessation following treatment with nicotine replacement therapy. Cancer Epidemiology, Biomarkers & Prevention 2006; 15:154-157
  152. Paoletti P, Fornai E, Maggiorelli F, et al. Importance of baseline cotinine plasma values in smoking cessation: Results from a double-blind study with nicotine patch. Eur Respir J 1996; 9:643-651
  153. Sachs DPL, Benowitz NL. Individualizing medical treatment for tobacco dependence. Eur Respir J 1996; 9:629-631
  154. Hurt RD. Percent cotinine replacement and probability of stopping smoking, 1995
  155. Sachs DPL. Effectiveness of the 4-mg dose of nicotine polacrilex for the initial treatment of high-dependent smokers. Arch Intern Med 1995; 155:1973-1980.
  156. Patten CA, Drews AA, Myers MG, et al. Effect of depressive symptoms on smoking abstinence and treatment adherence among smokers with a history of alcohol dependence. Psychol Addict Behav 2002; 16:135-142
  157. Chengappa KN, Kambhampati RK, Perkins K, et al. Bupropion sustained release as a smoking cessation treatment in remitted depressed patients maintained on treatment with selective serotonin reuptake inhibitor antidepressants. J Clin Psychiatry 2001; 62:503-508
  158. Doll R, Peto R, Wheatley K, et al. Mortality in relation to smoking: 40 years’ observations on male British doctors. Bmj 1994; 309:901-911.
  159. Breslau N, Schultz LR, Johnson EO, et al. Smoking and the risk of suicidal behavior: a prospective study of a community sample. Arch Gen Psychiatry 2005; 62:328-334
  160. Boden JM, Fergusson DM, Horwood LJ. Cigarette smoking and suicidal behaviour: results from a 25-year longitudinal study. Psychol Med 2008; 38:433-439
  161. Clemmey P, Brooner R, Chutuape MA, et al. Smoking habits and attitudes in a methadone maintenance treatment population. Drug Alcohol Depend 1997; 44:123-132
  162. Lemon S, Friedmann P, Stein M. The impact of smoking cessation on drug abuse treatment outcome. Addictive Behaviors 2003; 28:1323-1331
  163. Patkar A, Vergare M, Thornton C, et al. Nicotine dependence and treatment outcome among African American cocaine-dependent patients. Nicotine Tob Res 2003; 5:411-418
  164. Patkar AA, Gopalakrishnan R, Berrettini WH, et al. Differences in platelet serotonin transporter sites between African-American tobacco smokers and non-smokers. Psychopharmacology (Berl) 2003; 166:221-227
  165. Patkar A, Mannelli P, Peindl K, et al. Changes in tobacco smoking following treatment for cocaine dependence. American Journal of Drug & Alcohol Abuse 2006; 32:135-148
  166. Perkins KA, Donny E, Caggiula AR. Sex differences in nicotine effects and self-administration: review of human and animal evidence. Nicotine Tob Res 1999; 1:301-315
  167. Perkins KA. Smoking cessation in women. Special considerations. CNS Drugs 2001; 15:391-411
  168. Leventhal AM, Waters AJ, Boyd S, et al. Gender differences in acute tobacco withdrawal: effects on subjective, cognitive, and physiological measures. Exp Clin Psychopharmacol 2007; 15:21-36
  169. Schnoll RA, Patterson F, Lerman C. Treating tobacco dependence in women. J Womens Health (Larchmt) 2007; 16:1211-1218
  170. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296:47-55
  171. Williamson DF, Madans J, Anda RF, et al. Smoking cessation and severity of weight gain in a national cohort. N Engl J Med 1991; 324:739-745
  172. Smith SS, Jorenby DE, Leischow SJ, et al. Targeting smokers at increased risk for relapse: treating women and those with a history of depression. Nicotine Tob Res 2003; 5:99-109
  173. Kattapong V, Locher T, Secker-Walker R, et al. Tobacco-Cessation Patient Counseling: American College of Preventive Medicine Practice Policy Statement. Am J Prev Med 1998; 15:160-162
  174. Smoking and health: physician responsibility. CHEST 1995; 108:1118-1121
  175. Solberg L, Boyle R, Davidson G, et al. Patient satisfaction and discussion of smoking cessation during clinical visits. Mayo Clinical Proceedings 2001; 76:138-143
  176. Doll R, Peto R, Boreham J, et al. Mortality in relation to smoking: 50 years’ observations on male British doctors. BMJ 2004; 328:1519
  177. Tønnesen P, Carrozzi L, Fagerstrom KO, et al. Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. Eur Respir J 2007; 29:390-417
  178. Strunk R, Sternberg A, Szefler S, et al. Childhood Asthma Management Program (CAMP) Research Group. Long-term budesonide or nedocromil treatment, once discontinued, does not alter the course of mild to moderate asthma in children and adolescents. J Pediatr 2009; 154:682-687
  179. Grenhoff J, Svensson TH. Pharmacology of nicotine. British Journal of Addiction 1989; 84:477-492
  180. Nomikos G, Schilstrom B, Hildebrand B, et al. Role of alpha7 nicotinic receptors in nicotine dependence and implications for psychiatric illness. Behav Brain Res 2000; 113:97-103
  181. Picciotto MR, Corrigall WA. Neuronal systems underlying behaviors related to nicotine addiction: neural circuits and molecular genetics. J Neurosci 2002; 22:3338-3341
  182. Wonnacott S, Sidhpura N, Balfour D. Nicotine: from molecular mechanisms to behaviour. Curr Opin Pharmacol 2005; 5:53-59
  183. Rose J. Multiple brain pathways and receptors underlying tobacco addiction. Biochem Pharmacol 2007; 74:1263-1270
  184. Benowitz NL. Neurobiology of nicotine addiction: implications for smoking cessation treatment. Am J Med 2008; 121:S3-10
  185. Benowitz NL. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin Pharmacol Ther 2008; 83:531-541
  186. Gandhi K, Foulds J, Steinberg, et al. Lower quit rates among African American and Latino menthol cigarette smokers at a tobacco treatment clinic. Int J Clin Pract 2009; 63:360-367
  187. Swartz S, Gonzales D, Billing C, et al. The Effect of Nicotine Dependence Level on Quit Outcomes with Varenicline: Results from a Pooled-Analysis of Controlled Trials. Society for Research on Nicotine & Tobacco, 13th Annual Meeting. Austin, TX, 2007
  188. MHRA. Report of the Committee on Safety of Medicines Working Group on Nicotine Replacement Therapy. In: Medicines CoSo, ed: Medicines and Healthcare Products Regulatory Agency (UK), 2005; 20
  189. West R. Access To and Use of Aids [Medications] to Smoking Cessation in the UK [United Kingdom]. Society for Research on Nicotine & Tobacco, 13th Annual Meeting. Austin, TX, 2007
  190. Kornitzer M, Boutsen M, Dramaix M, et al. Combined use of nicotine patch and gum in smoking cessation: A placebo- controlled clinical trial. Prev Med 1995; 24:41-47
  191. Croghan I, Hurt R, Dakhil S, et al. Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention. Mayo Clinical Proceedings 2007; 82:186-195
  192. Ebbert J, Burke M, Hays J. Combination treatment with varenicline and nicotine replacement therapy. Nicotine Tob Res 2009; 11:572-576
  193. Ebbert J, Croghan I, Sood A, et al. Varenicline and bupropion sustained-release combination therapy for smoking cessation. Nicotine Tob Res 2009; 11:234-239
  194. Piper M, Smith S, Schlam T, et al. Efficacy of Three Single and Two Combination Pharmacotherapies Among Daily Smokers: A Randomized Placebo-Controlled Clinical Trial. Society for Research on Nicotine & Tobacco, 15th Annual Meeting. Dublin, Ireland, 2009
  195. Foulds J. The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline. Int J Clin Pract 2006; 60:571-576
  196. Johnson BA. New weapon to curb smoking: no more excuses to delay treatment. Arch Intern Med 2006; 166:1547-1550
  197. Kroenke K, Spitzer R, Williams J. The PHQ-9: Validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606-613
  198. Beck A, Steer R. Internal consistencies of the original and revised Beck Depression Inventory. Journal of Clinical Psychology 1984; 40:1365-1367
  199. Hodgkin J, Sachs D, Swan G, et al. Stop Smoking Success in the St. Helena Smoke-Free Life Residential Program. Society for Research on Nicotine and Tobacco International Conference. Dublin, Ireland, 2009
  200. Covey LS, Glassman AH, Stetner F. Depression and depressive symptoms in smoking cessation. Compr Psychiatry 1990; 31:350-354
  201. Sachs D, Fortmann S, Ferry L, et al. Suicidality, Varenicline, and Tobacco-Caused Mortality: A Perspective. JAMA 2009; In Preparation
  202. Stapleton JA, Watson L, Spirling LI, et al. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction 2008; 103:146-154
  203. Stapleton J. Do the 10 UK suicides among those taking the smoking cessation drug varenicline suggest a causal link? . Addiction 2009; 104:864-865
  204. Hayford KE, Patten CA, Rummans TA, et al. Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. Br J Psychiatry 1999; 174:173-178
  205. Ahluwalia JS, Harris KJ, Catley D, et al. Sustained-release bupropion for smoking cessation in African Americans: A randomized controlled trial. JAMA 2002; 288:468-474
  206. Muramoto ML, Leischow SJ, Sherrill D, et al. Randomized, double-blind, placebo-controlled trial of 2 dosages of sustained-release bupropion for adolescent smoking cessation. Arch Pediatr Adolesc Med 2007; 161:1068-1074
  207. Swan GE, McAfee T, Curry SJ, et al. Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial. Arch Intern Med 2003; 163:2337-2344
  208. Fossati R, Apolone G, Negri E, et al. A double-blind, placebo-controlled, randomized trial of bupropion for smoking cessation in primary care. Arch Intern Med 2007; 167:1791-1797
  209. Gonzales DH, Nides MA, Ferry LH, et al. Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study. Clin Pharmacol Ther 2001; 69:438-444
  210. Dale LC, Ebbert JO, Hays JT, et al. Treatment of nicotine dependence. Mayo Clin Proc 2000; 75:1311-1316
  211. Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005; 48:3474-3477
  212. Mihalak KB, Carroll FI, Luetje CW. Varenicline is a partial agonist at {alpha}4{beta}2 and a full agonist at {alpha}7 neuronal nicotinic receptors. Mol Pharmacol 2006
  213. Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006; 166:1561-1568
  214. Shiffman S, Dresler CM, Hajek P, et al. Efficacy of a nicotine lozenge for smoking cessation. Arch Intern Med 2002; 162:1267-1276
  215. Lunell E, Bergström M, Nordberg A. Nicotine deposition and body distribution from a nicotine inhaler and a cigarette studied with positron emission tomography. Clin Pharmacol Ther 1996; 59:593-594
  216. Henningfield JE, Radzius A, Cooper TM, et al. Drinking coffee and carbonated beverages blocks absorption of nicotine from nicotine polacrilex gum. JAMA 1990; 264:1560-1564
  217. McLaughlin K. Sending Smoke Signals: Cigarettes Without Tobacco. Mercury News. San Jose: McClatchy Publishing, 2009; 1A-2A
  218. Mahmarian JJ, Moye LA, Nasser GA, et al. Nicotine patch therapy in smoking cessation reduces the extent of exercise-induced myocardial ischemia. J Am Coll Cardiol 1997; 30:125-130
  219. Working Group for the Study of Transdermal Nicotine in Patients with Coronary Artery Disease. Nicotine replacement therapy for patients with coronary artery disease. Arch Intern Med 1994; 154:989-995
  220. Duff G. New [UK] Advice on Use of Nicotine Replacement Therapy (NRT): Wider Access in At-Risk Populations. In: (MHRA) MaHPRA, ed. UK: MHRA, 2005
  221. Miller M, Hemenway D, Bell NS, et al. Cigarette smoking and suicide: a prospective study of 300,000 male active-duty Army soldiers. Am J Epidemiol 2000; 151:1060-1063
  222. Miller M, Hemenway D, Rimm E. Cigarettes and suicide: a prospective study of 50,000 men. Am J Public Health 2000; 90:768-773
  223. Schneider B, Schnabel A, Weber B, et al. Nicotine use in suicides: a case-control study. Eur Psychiatry 2005; 20:129-136
  224. Malone KM, Waternaux C, Haas GL, et al. Cigarette smoking, suicidal behavior, and serotonin function in major psychiatric disorders. Am J Psychiatry 2003; 160:773-779
  225. Pollock M, Lee J. Postmarket Reviews: The Smoking Cessation Aids Varenicline (Marketed as Chantix) and Bupropion (Marketed as Zyban and Generics) – Suicidal Ideation and Behavior. FDA Drug Safety Newsletter, 2009; 1-4
  226. CDC. Suicide: Facts At A Glance. 2008; Summer:1-2
  227. CDC. Smoking-Attributable Mortality, Years of Potential Life Lost, and Productivity Losses – United States, 2000-2004. MMWR 2008; 57:1226-1228
  228. Hall SM, Humfleet GL, Reus VI, et al. Psychological intervention and antidepressant treatment in smoking cessation. Arch Gen Psychiatry 2002; 59:930-936
  229. Hall SM, Gorecki JA, Reus VI, et al. Belief about drug assignment and abstinence in treatment of cigarette smoking using nortriptyline. Nicotine Tob Res 2007; 9:467-471
  230. Steinberg M, Greenhaus S, Schmelzer A, et al. Triple-combination pharmacotherapy for medically ill smokers: a randomized trial. Ann Intern Med 2009; 150:447-454
  231. Hurt RD, Wolter TD, Rigotti N, et al. Bupropion for pharmacologic relapse prevention to smoking: predictors of outcome. Addict Behav 2002; 27:493-507
  232. Food and Drug Administration, ed. Zyban. Prescribing Information. Washington, DC: U.S. Department of Health and Human Services, 2003
  233. Fiore MC, Bailey WC, Cohen SJ, et al. You Can Quit Smoking. Consumer Guide (Based on Public Health Service Clinical Practice Guideline. Treating Tobacco Use and Dependence). Rockville, MD: U.S. Department of Health and Human Services. Public Health Service, 2000
  234. Fiore MC, Bailey WC, Cohen SJ, et al. Treating Tobacco Use and Dependence. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service, 2000
  235. Tønnesen P, Fryd V, Hansen M, et al. Effect of nicotine chewing gum in combination with group counseling on the cessation of smoking. N Engl J Med 1988; 318:15-18
  236. Sutherland G, Stapleton JA, Russell MA, et al. Randomised controlled trial of nasal nicotine spray in smoking cessation. Lancet 1992; 340:324-329
  237. Hajek P, Belcher M, Feyerabend C. Preference for 2 mg versus 4 mg nicotine chewing gum. Br J Addict 1988; 83:1089-1093
  238. Killen JD, Fortmann SP, Telch MJ, et al. Are heavy smokers different from light smokers? A comparison after 48 hours without cigarettes. JAMA 1988; 260:1581-1585
  239. Hughes JR. Treatment of smoking cessation in smokers with past alcohol/drug problems. J Subst Abuse Treat 1993; 10:181-187
  240. Glassman AH, Helzer JE, Covey LS, et al. Smoking, smoking cessation, and major depression. JAMA 1990; 264:1546-1549
  241. Killen JD, Fortmann SP, Newman B, et al. Evaluation of a treatment approach combining nicotine gum with self-guided behavioral treatments for smoking relapse prevention. J Consult Clin Psychol 1990; 58:85-92
  242. Sachs DPL, Leischow SJ. Differential gender treatment response: effectiveness of the 4 mg dose of nicotine polacrilex to treat low nicotine dependent male smokers but not women. Problems of Drug Dependence 1992: Proceeding of the 54th Annual Scientific Meeting. Keystone, CO, 1992
  243. Fagerström KO, Sachs DPL. Medical Management of Tobacco Dependence: A Critical Review of Nicotine Skin Patches. Current Pulmonology 1995; 16:223-238
  244. Sachs DPL, Bostrom AG, Hansen MD. Nicotine patch therapy: Predictors of smoking cessation success. Am J Respir Crit Care Med 1994; 149:A326
  245. Lillington GA, Leonard CT, Sachs DPL. Smoking cessation. Techniques and benefits. Clin Chest Med 2000; 21:xi, 199-208
  246. Fiore MC. Treating tobacco use and dependence: an introduction to the US Public Health Service Clinical Practice Guideline. Respir Care 2000; 45:1196-1199.
  247. American Congress in Obstetrics and Gynecology. Smoking cessation during pregnancy committee opinion #316. Obstetrics and gynecology 2005; 106:883-888.
  248. United States Department of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2004.
  249. United States Department of Health and Human Services. Women and Smoking: A Report of the Surgeon General. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2001.
  250. Henningfield JE, London ED, Benowitz NL. Arterial-venous differences in plasma concentrations of nicotine after cigarette smoking. JAMA 1990; 263:2049-2050
  251. United States Department of Health and Human Services. The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Coordinating Center for Health Promotion, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2006.
  252. Lancaster T, Stead L. Self-help interventions for smoking cessation: The Cochrane database of systematic reviews 2005, 2005
  253. Bronson D. Review: self help interventions for smoking cessation are not effective unless tailored to the individual. Evidence-based medicine 2006; 11:48
  254. Naughton F, Prevost A, Sutton S. Self-help smoking cessation interventions in pregnancy: a systematic review and meta-analysis. Addiction 2008; 103:566-579
  255. Stotts A, Diclemente C, Dolan-Mullen P. One-to-one: a motivational intervention for resistant pregnant smokers. Addict Behav 2002; 27:275-292
  256. Lancaster T, Stead L. Individual behavioural counselling for smoking cessation: The Cochrane database of systematic reviews, 2005
  257. Stead L, Lancaster T. Group behaviour therapy programmes for smoking cessation: The Cochrane database of systematic reviews, 2005
  258. Crawford J, Tolosa J, Goldenberg R. Smoking cessation in pregnancy: why, how, and what next. Clin Obstet Gynecol 2008; 51:419-435
  259. Dempsey DA, Benowitz NL. Risks and benefits of nicotine to aid smoking cessation in pregnancy. Drug Saf 2001; 24:277-322
  260. Drugs for tobacco dependence. Treat Guidel Med Lett 2008; 6:61-66
  261. Chan B, Einarson A, Koren G. Effectiveness of bupropion for smoking cessation during pregnancy. Journal of Addictive Diseases 2005; 24:19-23
  262. Cole J, Modell J, Haight B, et al. Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiology and Drug Safety 2007; 16:474-484
  263. Chun-Fai-Chan B, Koren G, Fayez I, et al. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. American journal of obstetrics and gynecology 2005; 192:932-936
  264. Pfizer. Chantix™ (varenicline) Tablets Prescribing Information: Pfizer Labs Division of Pfizer Inc., 2008; 1-19
  265. Peterson E, Johnson C, Ownby D. Use of urinary cotinine and questionnaires in the evaluation of infant exposure to tobacco smoke in epidemiologic studies. Journal of clinical epidemiology 1997; 50:917-923
  266. Farber H, Knowles S, Brown N, et al. Secondhand tobacco smoke in children with asthma: sources of and parental perceptions about exposure in children and parental readiness to change. Chest 2008; 133:1367-1374
  267. Elders MJ, Perry CL, Eriksen MP, et al. The report of the Surgeon General: preventing tobacco use among young people. Am J Public Health 1994; 84:543-547
  268. Sockrider M. The role of the pediatrician in smoking prevention. Current Opinion in Pediatrics 1997; 9:225-229
  269. Winickoff J, Tanski S, McMillen R, et al. A national survey of the acceptability of quitlines to help parents quit smoking. Pediatrics 2006; 117:e695-700
  270. Winickoff J, Berkowitz A, Brooks K, et al. State-of-the-art interventions for office-based parental tobacco control. Pediatrics 2005; 115:750-760
  271. American Academy of Pediatrics Committee on Substance Abuse. Tobacco’s Toll: Implications for the Pediatrician. Pediatrics 2001; 107:794-798.
  272. Farber H, Wilson S, Caine L, et al. Association between parent report of smoke exposure level, effect of smoke on child’s asthma, and urine cotinine levels. American Thoracic Society International Conference. San Diego, CA, 2005
  273. Benowitz NL. Biomarkers of Environmental Tobacco Smoke Exposure. Environ Health Perspect 1999; 107:349-355
  274. Kim H, Lim Y, Lee S, et al. Relationship Between Environmental Tobacco Smoke And Urinary Cotinine Levels In Passive Smokers At Their Residence. Journal Of Exposure Analysis And Environmental Epidemiology 2004; 14:S65-S70
  275. Winickoff J, Tanski S, McMillen R, et al. Child Health Care Clinicians’ Use of Medications to Help Parents Quit Smoking: A National Parent Survey. Pediatrics 2005; 115:1013-1017
  276. Hanson K. Patterns of insurance coverage within families with children. Health Affairs (Millwood) 2001; 20:240-246
  277. Park M, Paul M, Adams S, et al. The health status of young adults in the United States. J Adolesc Health 2006; 39:305-317
  278. Prochaska J, Velicer W. The transtheoretical model of health behavior change. Am J Health Promot 1997; 12:38-48
  279. Norcross J, Prochaska J. Using the stages of change. Harv Ment Health Lett 2002; 18:5-7
  280. Colby SM, Tiffany ST, Shiffman S, et al. Are adolescent smokers dependent on nicotine? A review of the evidence. Drug Alcohol Depend 2000; 59 Suppl 1:S83-95
  281. CDC. Fact Sheet Youth and Tobacco Use: Current Estimates (updated December 2006): CDC, 2008
  282. Curry S. Youth tobacco cessation: filling the gap between what we do and what we know. Am J Health Behav 2003; 27:S99-S1102
  283. Sussman S, Sun P, Dent C. A meta-analysis of teen cigarette smoking cessation. Health Psychol 2006; 25:549-557
  284. Horn K, Fernandes A, Dino G, et al. Adolescent nicotine dependence and smoking cessation outcomes. Addictive Behaviors 2003; 28:769-776
  285. Moolchan E, Robinson M, Ernst M, et al. Safety and Efficacy of the Nicotine Patch and Gum for the Treatment of Adolescent Tobacco Addiction. Pediatrics 2005; 115:407-414
  286. Prokhorov A, Pallonen U, Fava J, et al. Measuring nicotine dependence among high-risk adolescent smokers. Addict Behav 1996; 21:117-127
  287. Prokhorov A, de Moor C, Pallonen U, et al. Validation of the modified Fagerström tolerance questionnaire with salivary cotinine in adolescents. Addict Behav 2000; 25:429-433
  288. Wheeler K, Fletcher K, Wellman R, et al. Screening adolescents for nicotine dependence: the Hooked On Nicotine Checklist. J Adolesc Health 2004; 35:225-230
  289. Adelman W. Nicotine replacement therapy for teenagers: About time or a waste of time? Arch Pediatr Adolesc Med 2004; 158:205-206
  290. Wellman R, DiFranza J, Savageau J, et al. Short term patterns of early smoking acquisition. Tobacco Control 2004; 13:251-257
  291. Adelman W. Tobacco use cessation in adolescents. Adolescent Medicine Clinics 2006; 17:697-717
  292. Kimmel S, Berlin J, Miles C, et al. Risk of acute first myocardial infarction and use of nicotine patches in a general population. J Am Coll Cardiol 2001; 37:1297-1302
  293. Murray RP, Bailey WC, Daniels K, et al. Safety of nicotine polacrilex gum used by 3,094 participants in the Lung Health Study. Lung Health Study Research Group. Chest 1996; 109:438-445
  294. Orleans CT, Resch N, Noll E, et al. Use of transdermal nicotine in a state-level prescription plan for the elderly. A first look at ‘real-world’ patch users. JAMA 1994; 271:601-607
  295. Hasford J, Fagerstrom K, Haustein K. A naturalistic cohort study on effectiveness, safety and usage pattern of an over-the-counter nicotine patch. Cohort study on smoking cessation. Eur J Clin Pharmacol 2003; 59:443-447
  296. McNeill A, Hendrie A. Regulation of Nicotine Replacement Therapies: An Expert Consensus. In: Project WHOEP, ed. Copenhagen: World Health Organization Europe, 2001
  297. American Academy of Pediatrics Committee on Environmental Health. Environmental Tobacco Smoke: A Hazard to Children. Pediatrics 1997; 99:639-642.
  298. Wellman R, Sugarman D, DiFranza J, et al. The extent to which tobacco marketing and tobacco use in films contribute to children’s use of tobacco: a meta-analysis. Arch Pediatr Adolesc Med 2006; 160:1285-1296
  299. Charlesworth A, Glantz S. Smoking in the movies increases adolescent smoking: A Review. Pediatrics 2005; 116:1516-1528
  300. Curry SJ, Emery S, Sporer AK, et al. A national survey of tobacco cessation programs for youths. Am J Public Health 2007; 97:171-177
  301. Sockrider M. Addressing Tobacco smoke exposure: Passive and Active. Pediatr Pulmonl Suppl 2004; 26:183-187
  302. Hennrikus DJ, Jeffery RW, Lando HA. Occasional smoking in a Minnesota working population. Am J Public Health 1996; 86:1260-1266
  303. Hassmiller KM, Warner KE, Mendez D, et al. Nondaily smokers: who are they? Am J Public Health 2003; 93:1321-1327
  304. Oksuz E, Mutlu ET, Malhan S. Characteristics of daily and occasional smoking among youths. Public Health 2007; 121:349-356
  305. Gilpin E, Cavin SW, Pierce JP. Adult smokers who do not smoke daily. Addiction 1997; 92:473-480
  306. Wortley PM, Husten CG, Trosclair A, et al. Nondaily smokers: a descriptive analysis. Nicotine Tob Res 2003; 5:755-759
  307. Fergusson DM, Horwood LJ. Transitions to cigarette smoking during adolescence. Addict Behav 1995; 20:627-642
  308. Tong EK, Ong MK, Vittinghoff E, et al. Nondaily smokers should be asked and advised to quit. Am J Prev Med 2006; 30:23-30
  309. Rubinstein M, Benowitz N, Auerback G, et al. Withdrawal in adolescent light smokers following 24-hour abstinence. Nicotine Tob Res 2009; 11:185-189
  310. Centers for Disease Control and Prevention. Prevalence of current cigarette smoking among adults and changes in prevalence of current and some day smoking-United States, 1996-2001. MMWR Morb Mortal Wkly Rep. 2003; 52:303-307
  311. Pierce J, White M, Messer K. Changing age-specific patterns of cigarette consumption in the United States, 1992-2002: Association with smoke-free homes and state-level tobacco control activity. Nicotine Tob Res 2009; 11:171-177
  312. Trinidad D, Perez-Stable EJ, Emery S, et al. Intermittent and light daily smoking across racial/ethnic groups in the United States. Nicotine Tob Res 2009; 11:203-210
  313. Harrison E, Desai R, McKee S. Nondaily smoking and alcohol use, hazardous drinking, and alcohol diagnoses among young adults: findings from the NESARC. Alcohol Clin Exp Res 2008; 32:2081-2087
  314. White H, Bray B, Fleming C, et al. Transitions into and out of light and intermittent smoking during emerging adulthood. Nicotine Tob Res 2009; 11:211-219
  315. Surgeon General. The Health Consequences of Smoking. In: Service PH, ed. Rockville: US Department of Health and Human Services, 2004; 941
  316. Wilson D, Parsons J, Wakefield M. The health-related quality-of-life of never smokers, ex-smokers, and light, moderate, and heavy smokers. Prev Med 1999; 29:139-144
  317. . Philip Morris, 1988; 2057041812/2057041833
  318. Luoto R, Uutela A, Puska P. Occasional smoking increases total and cardiovascular mortality among men. Nicotine Tob Res 2000; 2:133-139
  319. US Department of Health, Education, and Welfare. Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service. Public Health Service Publication No. 1103 ed. Rockville (MD): United States Public Health Service, Office of the Surgeon General, 1964.
  320. Moran S, Wechsler H, Rigotti NA. Social smoking among US college students. Pediatrics 2004; 114:1028-1034
  321. Waters K, Harris K, Hall S, et al. Characteristics of social smoking among college students. J Am Coll Health 2006; 55:133-139
  322. Levinson AH, Campo S, Gascoigne J, et al. Smoking, but not smokers: identity among college students who smoke cigarettes. Nicotine Tob Res 2007; 9:845-852
  323. Schane R, Glantz S, Ling P. Social Smoking: Implications for Public Health and Clinical Practice. Am J Prev Med 2009; In press
  324. Casual (23 Percent) Social Smoker. Philip Morris, 1989; 2057041843/2057041846
  325. Services) SGUDoHaH. Treating Tobacco Use and Dependence:2008 Update-Clinical Practice Guidelines 2008
  326. Smoking Attitudes. (1990/1991 (900000/910000) Segmentation Study). RJ Reynolds, 1991; 507747209/507747224
  327. Society for Medical Decision-Making Committee. Proposal for clinical algorithm standards, SMDMC on Standardization of Clinical Algorithms. Medical Decision Making 1992; 12:149-154.
  328. Prokhorov A, Koehly L, Pallonen U, et al. Adolescent nicotine dependence measured by the Modified Fagerström Tolerance Questionnaire at two time points. Journal of Child & Adolescent Substance Abuse 1998; 7:35-47
  329. Wellman R, DiFranza J, Pbert L, et al. Comparison of the Psychometric Properties of the Hooked on Nicotine Checklist and the Modified Fagerström Tolerance Questionnaire. Addict Behav 2006; 31:486-495
  330. Wellman R, Savageau J, Godiwala S, et al. A comparison of the Hooked on Nicotine Checklist and the Fagerstrom Test for Nicotine Dependence in adult smokers. Nicotine and Tobacco Research 2006; 8:575-580
  331. Weinberger AH, Reutenauer EL, Allen TM, et al. Reliability of the Fagerstrom Test for Nicotine Dependence, Minnesota Nicotine Withdrawal Scale, and Tiffany Questionnaire for Smoking Urges in smokers with and without schizophrenia. Drug Alcohol Depend 2007; 86:278-282
  332. Beck A, Steer R, Carbin M. Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. Clinical Psychology Review 1988:77-100
  333. Radloff L. The CES-D scale: A self-report depression scale for research in the general population. Applied Psychological Measurement 1977; 1:333-339
  334. Shacham S. A Shortened Version of the Profile of Mood States. Journal of Personality Assessment 1983; 47:305-306
  335. Borg G. Psychophysical basis of perceived exertion. Med Sci Sports Exerc 1982; 14:377-381
  336. Elliott M, Adams L, Cockcroft A, et al. The language of breathlessness. Am Rev Respir Dis 1991; 144:826-832
  337. Jones P, Quirck F, Baveystock C. The St George’s Respiratory Questionnaire. Respir Med 1991; 85 (Suppl. B):25-31
  338. Stark R, Gambles S, Chatterjee S. An exercise test to assess clinical dyspnea:
  339. DiFranza J, Savageau J, Fletcher K, et al. Measuring the loss of autonomy over nicotine use in adolescents: the DANDY (Development and Assessment of Nicotine Dependence in Youths) study. Archives of pediatrics & adolescent medicine 2002; 156:397-403
  340. MacPherson L, Strong D, Meyers M. Using an item response model to examine the nicotine dependence construct as characterized by the HONC and the mFTQ among adolescent smokers. Addict Behav 2008; 33:880-894
  341. DiFranza J, Wellman R. Hooked on Nicotine Checklist (HONC): UMass Medical School. Family Medicine & Community Health 2006
  342. Hatsukami DK, Hughes JR, Pickens RW, et al. Tobacco withdrawal symptoms: An experimental analysis. Psychopharmacology 1984; 84:231-236
  343. Hughes J. In: Sachs D, ed, 2009
  344. Kohn L, Corrigan J, Donaldson M, et al. To err is human: building a safer health system. In: Academies TN, ed. Washington, 2000
  345. Committee on Quality of Health Care in America. Crossing the quality chasm: a new health system for the 21st century. In: Press NA, ed. Washington: Institute of Medicine, 2001.
  346. The Campaign for Smokefree Air. Make Michigan Air Smokefree, 2008. URL: http://www.makemiairsmokefree.com/
  347. U.S. Department of Health and Human Services. The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Coordinating Center for Health Promotion, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2006
  348. Sargent RP, Shepard RM, Glantz SA. Reduced incidence of admissions for myocardial infarction associated with public smoking ban: before and after study. Bmj 2004; 328:977-980
  349. CDC. Reduced Hospitalizations for Acute Myocardial Infarction After Implementation of a Smoke-Free Ordinance — City of Pueblo, Colorado, 2002–2006. MMWR 2009; 57:1373-1377
  350. Pell J, Haw S, Stuart C, et al. Smoke-free Legislation and Hospitalizations for Acute Coronary Syndrome. NEJM 2008; 359:482-491
  351. Cesaroni G, Forastiere F, Agabiti N, et al. Effect of the Italian Smoking Ban on Population Rates of Acute Coronary Events. Circulation 2008; 117:1183-1188
  352. Cains T, Cannnata S, Poulos R, et al. Designated “No Smoking” areas provide from partial to no protection from environmental tobacco smoke. Tobacco Control 2004; 13:17-22
  353. Hyland A, Puli V, Cummings M, et al. New York’s Smoke-free Regulations: Effects on Employment and Sales in the Hospitality Industry. Cornell Hotel and Restaurant Adminstration Quarterly 2003; 44:9-16
  354. Scollo M, Lal A, Hyland A, et al. Review of the quality of studies on the economic effects of smoke-free policies on the hospitality industry. Tob Control 2003; 12:13-20
  355. Scollo M, Lal A. Summary of Studies Assessing the Economic Impact of Smoke-Free Policies in the Hospitality Industry. Melbourne, Australia: VicHealth Centre for Tobacco Control, The Cancer Council Victoria, 2008
  356. Glantz SA, Charlesworth A. Tourism and hotel revenues before and after passage of smoke-free restaurant ordinances. Jama 1999; 281:1911-1918
  357. Stoddard J, Gray B. Maternal Smoking and Medical Expenditures for Childhood Respiratory Illness. American Journal of Public Health 1997; 87:205-209
  358. Farber S. Statement on cancer of the lung. CHEST 1960; 37:248
  359. ACCP. Formal Recommendations of The National Forum on Office Management of Smoking Problems. Dis Chest 1968; 54:169-220
  360. Fredrickson D. Cigarette Smoking: Questions Patients Ask Doctors (Part 2). CHEST 1970; 58:369-372
  361. Fredrickson D. Cigarette Smoking: Questions Patients Ask Doctors (Part 1). CHEST 1970; 58:147-151
  362. Frederickson D. The Primary Physician in Office Management of Smoking Problems. CHEST 1971; 59:414-417
  363. ACCP. The management of smoking in the physician’s “workshop”. CHEST 1982; 82:359-361
  364. NHLBI issues updated guidelines for the diagnosis and management of asthma. Am Fam Physician. 1997 Aug;56(2):621-3. PubMed PMID: 9262536.
  365. The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General. In: Services HaH, ed. Rockville MD: US GPO, 2006.